Matches in SemOpenAlex for { <https://semopenalex.org/work/W2732518809> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2732518809 endingPage "S642" @default.
- W2732518809 startingPage "S642" @default.
- W2732518809 abstract "Antidepressant drugs selective inhibitors of serotonin reuptake (IRS) are the drugs effective in obsessive compulsive disorder. It has not been proven more effective none of them except clomipramine. Around 40–60% of the Patients with obsessive-compulsive disorder (OCD) remain unimproved by serotonin reuptake inhibitors (SRIs). Two cases are presented in relation to this disorder and its treatment. Twenty-three year old woman begins to present anhedonia, apathy, isolation and low mood. Treatment was initiated with escitalopram with partial improvement. Obsessive component traits Thirty year old man with obsessive clinic of years of evolution, with worsening in recent months treatment with 200 mg sertraline. In both cases treatment with oral aripiprazole it was associated with a dose of 5 mg daily with improvement in obsessive symptoms. Results The efficacy of aripiprazole as adjunctive drug treatment and obsessive anxiety is observed. However, we must take into account the potential risks posed as neuroleptic malignant syndrome and QTc prolongation. Conclusion Aripiprazole is an antipsychotic which has a novel mechanism of action to be a partial agonist of dopamine D2 receptors. This fact has led to its inclusion in the group of antipsychotics called third generation, also called partial dopamine agonists, dopamine stabilizers or “dopamine-serotonin modulators system.” Its most common side effects such as nausea, headaches, agitation and akathisia were observed in studies on schizophrenia, schizoaffective disorder and bipolar disorder. Unlike other atypical antipsychotics, is considered a relatively neutral drug to weight gain, hyperprolactinemia, changes in metabolic parameters and sedation. Disclosure of interest The authors have not supplied their declaration of competing interest." @default.
- W2732518809 created "2017-07-14" @default.
- W2732518809 creator A5036949617 @default.
- W2732518809 creator A5043138907 @default.
- W2732518809 creator A5061032283 @default.
- W2732518809 date "2017-04-01" @default.
- W2732518809 modified "2023-09-25" @default.
- W2732518809 title "Antipsychotic Adjuvant Treatment in OCD" @default.
- W2732518809 doi "https://doi.org/10.1016/j.eurpsy.2017.01.1061" @default.
- W2732518809 hasPublicationYear "2017" @default.
- W2732518809 type Work @default.
- W2732518809 sameAs 2732518809 @default.
- W2732518809 citedByCount "0" @default.
- W2732518809 crossrefType "journal-article" @default.
- W2732518809 hasAuthorship W2732518809A5036949617 @default.
- W2732518809 hasAuthorship W2732518809A5043138907 @default.
- W2732518809 hasAuthorship W2732518809A5061032283 @default.
- W2732518809 hasConcept C118552586 @default.
- W2732518809 hasConcept C126322002 @default.
- W2732518809 hasConcept C15744967 @default.
- W2732518809 hasConcept C170493617 @default.
- W2732518809 hasConcept C2776174506 @default.
- W2732518809 hasConcept C2776412080 @default.
- W2732518809 hasConcept C2776809841 @default.
- W2732518809 hasConcept C2777270317 @default.
- W2732518809 hasConcept C2777393122 @default.
- W2732518809 hasConcept C2778938600 @default.
- W2732518809 hasConcept C2780057945 @default.
- W2732518809 hasConcept C2780211496 @default.
- W2732518809 hasConcept C2780494398 @default.
- W2732518809 hasConcept C2780733359 @default.
- W2732518809 hasConcept C58732023 @default.
- W2732518809 hasConcept C71924100 @default.
- W2732518809 hasConceptScore W2732518809C118552586 @default.
- W2732518809 hasConceptScore W2732518809C126322002 @default.
- W2732518809 hasConceptScore W2732518809C15744967 @default.
- W2732518809 hasConceptScore W2732518809C170493617 @default.
- W2732518809 hasConceptScore W2732518809C2776174506 @default.
- W2732518809 hasConceptScore W2732518809C2776412080 @default.
- W2732518809 hasConceptScore W2732518809C2776809841 @default.
- W2732518809 hasConceptScore W2732518809C2777270317 @default.
- W2732518809 hasConceptScore W2732518809C2777393122 @default.
- W2732518809 hasConceptScore W2732518809C2778938600 @default.
- W2732518809 hasConceptScore W2732518809C2780057945 @default.
- W2732518809 hasConceptScore W2732518809C2780211496 @default.
- W2732518809 hasConceptScore W2732518809C2780494398 @default.
- W2732518809 hasConceptScore W2732518809C2780733359 @default.
- W2732518809 hasConceptScore W2732518809C58732023 @default.
- W2732518809 hasConceptScore W2732518809C71924100 @default.
- W2732518809 hasIssue "S1" @default.
- W2732518809 hasLocation W27325188091 @default.
- W2732518809 hasOpenAccess W2732518809 @default.
- W2732518809 hasPrimaryLocation W27325188091 @default.
- W2732518809 hasRelatedWork W1950164447 @default.
- W2732518809 hasRelatedWork W1989280569 @default.
- W2732518809 hasRelatedWork W2004208579 @default.
- W2732518809 hasRelatedWork W2042749834 @default.
- W2732518809 hasRelatedWork W2086451860 @default.
- W2732518809 hasRelatedWork W2123286568 @default.
- W2732518809 hasRelatedWork W2137134006 @default.
- W2732518809 hasRelatedWork W2471688333 @default.
- W2732518809 hasRelatedWork W2732518809 @default.
- W2732518809 hasRelatedWork W4367627823 @default.
- W2732518809 hasVolume "41" @default.
- W2732518809 isParatext "false" @default.
- W2732518809 isRetracted "false" @default.
- W2732518809 magId "2732518809" @default.
- W2732518809 workType "article" @default.